ProCE Banner Activity

Optimizing Bispecific Antibody Therapy for R/R DLBCL: Answers to Frequently Asked Questions

Clinical Thought

Read this commentary with our answers to frequently asked questions about best practices for managing patients with R/R DLBCL with anti–CD3xCD20-directed bispecific antibodies, the benefits of community-based treatment, and best approaches for patient care.

Released: October 18, 2024

Expiration: October 17, 2025

Share

Faculty

Sherry Adkins

Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Kathleen Dorritie

Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology Oncology
UPMC, University of Pittsburgh
Pittsburgh, Pennsylvania

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Genmab US, Inc.

Genmab US, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Sherry Adkins, MSN, ANP-C, FAAN, has no relevant financial relationships to disclose.

Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology Oncology
UPMC, University of Pittsburgh
Pittsburgh, Pennsylvania

Kathleen Dorritie, MD: researcher (paid to institution): Bristol Myers Squibb, Genmab, Hoffmann-La Roche, Janssen, Kite/Gilead; advisor/speaker: Bristol Myers Squibb, Janssen.